Vedantra Pharmaceuticals, Inc. logo

Vedantra Pharmaceuticals, Inc.

An #immunotherapy company focused on developing products for #cancer and #infectiousdiseases Vedantra Pharmaceuticals Inc. (spinout from MIT), is developing nanoparticle vaccines that are designed to generate a more potent antibody and T cell response than traditional subunit vaccines.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://vedantra.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
One Kendall Square Bldg. 1400 West, Suite 14303, MA, 02139
Cambridge
United States
Email
Contact Number
+1 617-945-2077

In Mar 2017, Vedantra signed a joint collaboration to explore cancer vaccine research with Neon Therapeutics. Under the terms, the two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantras albumin-binding, lymph node targeting amphiphile technology with Neons neoantigen vaccine research.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vedantra-pharmaceuticals-inc.” connections=”true” suffix=””]

Vedantra subunit vaccine technology comprised of highly structured lipid nano-particles, that delivers antigens subunit and provides durable long lasting antibody and CTL responses. It co-packed antigens and molecular adjuvants, and have enhanced stability compare to liposomes due to high cross-linking.

In 2012, Vedantra received $3.3 Mn in equity funding from Access Bridge Gap Ventures.